In cancer cells, loss of E-cadherin gene expression caused dysfunction of the cell-cell junction system, triggering cancer invasion and metastasis. Therefore, E-cadherin is an important tumor-suppressor gene. To understand how E-cadherin gene expression is regulated in cancer cells, we have used E-cadherin-positive and -negative expressing cells to find out the possible up-or downregulating transcription factors in human E-cadherin regulatory sequences. Functional analysis of human E-cadherin regulatory sequences constructs indicated that AML1, Sp1, and p300 may play important roles in promoting E-cadherin expression. In addition, we found there are four HNF3-binding sites in human E-cadherin regulatory sequences. The exogenous HNF3 can enhance the E-cadherin promoter activity in metastatic breast cancer cells and the metastatic breast cancer cells stably transfected with HNF3 showed re-expression of E-cadherin. The HNF3 stable transfectants changed from mesenchymal-like into epithelial morphology. The transwell assays showed the re-expressed E-cadherin reduced cell motility of metastatic breast cancer cells. These results suggested HNF3 may play important roles in the upregulation of the E-cadherin promoter, with the consequent re-expression of E-cadherin, thus reducing the metastatic potential of breast cancer cells. These findings suggested HNF3 plays important roles in the upregulation of the E-cadherin gene and may be able to reduce the motility of metastatic breast cancer cells.
Introduction
Cancer can be regarded as the result of failure of the mechanism that mediates cell-cell interaction with its consequential loss of balance in maintaining a normal cell shape and polarity. There are various regulatory pathways (or processes) that maintain normal cell functions. Perturbation of these processes by either genetic or epigenetic changes will lead to cell death or, in the worst scenario, the appearance of cancer cells (Hanahan and Weinberg, 2000) . These changes can occur in either sequential steps or a few genetic changes. Eventually, these cancer cells will invade and break out of confinement of the adjacent tissues, and travel to distant sites (in most cases, preferentially) where they establish a new cancer colony. This spreading of cancer cells, or metastasis, is the cause of most cancer deaths (Fidler, 2003) . Tumor metastases are very complex processes. Their genetic, cell biological, and biochemical mechanisms are still very elusive. Thus, the elucidation of the mechanisms of metastasis has become the 'eventual campaign' for cancer research. Understanding these processes will help to illustrate the genetic and/or epigenetic changes that drive tumor metastasis. At the mechanistic level, for cancer cells to develop into metastatic cancer cells, at least four interrelated processes are involved: (a) activation of epithelialmesenchymal transition (EMT) (Thiery, 2002) , (b) remodeling of the extracellular matrix (ECM) (Sasisekharan et al., 2002) , (c) migration to specific secondary sites (Hood and Cheresh, 2002) , and (d) neoangiogenesis (Chambers et al., 2002) .
Normally, epithelial cells are tightly interconnected through several junctional structures, including tight junctions and adherens-type junctions, which are intimately associated with the actin and intermediate cytoskeleton. The activation of EMT allows cells to dissociate from the epithelial type to mesenchymal type. EMT is a process vital for morphogenesis during embryonic development and has also been implicated in the transition of early-stage tumors into invasive malignancies. This type of conversion results in the loss of cell-cell contacts and a dramatic remodeling of cytoskeleton in the epithelial cell layers (Duband et al., 1995; Viebanhn, 1995) . E-cadherin is a cell-cell adhesion molecule and the loss of its expression is a hallmark of EMT. Reduction of the E-cadherin increased cell mobility and promoted tumor cell invasion (Birchmeier and Behrens, 1994; Bussemakers et al., 1994; Berx et al., 1995) .
The loss of E-cadherin has been shown to be an important event for the invasion of epithelial tumor cells. Several mechanisms have revealed that the loss of E-cadherin expression can occur either genetically or epigenetically during tumor progression. (Takeichi, 1993; Christofori and Semb, 1999) . Hypermethylation and chromatin remodeling of the E-cadherin gene have emerged as the main mechanisms for the downregulation of E-cadherin in most carcinomas. The dysfunction in the regulation of E-cadherin expression plays an essential role in pathological processes such as tumor progression.
Promoter hypermethylation is known to result in transcriptional downregulation of many genes including the E-cadherin gene. It has been suggested that transcriptional downregulation resulted from promoter hypermethylation of the E-cadherin gene in many tumors, including breast carcinomas (Graff et al., 1995) , gastric carcinomas (Grady et al., 2000) , esophageal carcinoma (Si et al., 2001) , and oral/tongue carcinoma (Chang et al., 2000) . These results demonstrated that the E-cadherin promoter can be partially methylated. In general, the methylation profile of this E-cadherin promoter fragment contains unmethylated or partially methylated CpG islands.
Chromatin remodeling has also emerged as the transcriptional control of E-cadherin gene expression. There was a report showing that members of snail family transcription factor, the transcriptional repressors, were involved in histone deacetylation. (Hemavathy et al., 2000) . The acetylation or deacetylation status of histones at specific DNA regulatory sequence depended on the recruitment of histone acetyltransferase (HAT) or histone deacetylase (HDAC) to the regulatory sites (Strahl and Allis, 2000) . These factors may play a role as part of large multiprotein complexes of coactivators or corepressors (Peinado et al., 2004) .
The Snail family transcription factors have been shown to play major roles in E-cadherin repression and these factors have been proposed to act as inducers in the invasion process, including the zinc-finger factors snail (Batlle et al., 2000; Cano et al., 2000) and Slug (Bolos et al., 2003) . The two-handed zinc factors family, ZEB1 and ZEB2 (SIP-1), and the bHLH family factors, E12/E47, also demonstrated their downregulated effects to repress E-cadherin gene expression (Comijn et al., 2001; Perez-Moreno et al., 2001 ). An inverse correlation between the Twist and E-cadherin expression was also observed in invasive lobular breast carcinoma. The finding implicated the Twist in tumor cell intravasation, or entry into the circulation to seed metastases (Yang et al., 2004) . Most of these studies on E-cadherin expression had used mouse models. They have focused mostly on the E boxes which are near the transcription start site, and fewer studies focused on the whole genome context of the human E-cadherin gene.
The mechanisms of regulation of the E-cadherin gene in metastatic or nonmetastatic cells are still poorly understood. To study the regulation of E-cadherin gene expression in metastatic and nonmetastatic cancer cells, we focused on the methylation states, chromatin constraint and snail family transcription factors in downregulation of E-cadherin gene expression, thus enhancing metastatic potential. We also identified the upregulating transcription factors that could enhance Ecadherin gene expression, thus repressing the metastatic potential of cancer cells.
To investigate why, in mesenchymal looking metastatic cancer cell lines, E-cadherin was not expressed, we explored whether methylation or chromatin structural constrains played a role in E-cadherin expression. The results showed that nonexpression of the E-cadherin gene in metastatic melanoma cells A2058 and metastatic breast cancer cells MDA231 and MDA435 were caused by hypermethylation. We also found the chromatin structure put a constraint, in MDA231 and MDA435 cells, on E-cadherin expression. In addition, we found that p300, AML1, and HNF3 can serve as positive regulators. In a large context of E-cadherin gene regulation HNF3 was found to be a strong positive regulator. Our results indicated that HNF3 may have important functions, by interacting with the p300 and the AML1 to enhance the re-expression of E-cadherin, and to reduce the migratory potential of metastatic breast cancer cells.
Results

Structure and functions of human E-cadherin gene regulatory sequences
In order to understand how human E-cadherin gene expression is regulated, a 1.2 kb DNA fragment upstream from the transcription initiation site of human E-cadherin gene was cloned by genomic PCR and sequenced ( Figure 1 ). Several putative transcription factor-binding sites were identified by using the TFsearch software program. There are five Sp1-binding sites proximal to the transcription initiation site. There are 4 Eboxes that can be recognized by transcription factor snail: three proximal to the transcription initiation site and one at the middle of the cloned regulatory sequence. Distal to the transcription initiation site there are also three AML1-binding sites and two p300-binding sites. In addition, there are four HNF3-binding sites that are with distal, two of them overlapping with one another.
To explore the functions of the regulatory sequences of human E-cadherin gene, serial deletions of these sequences were constructed and attached with pGL3 luciferase reporter plasmid. These constructs were transfected into E-cadherin-positive (i.e. MCF7) or E-cadherin-negative (i.e. MDA231) cells, and luciferase activities were measured. As shown in Figure 2 , the E-cadherin-negative cells showed only the basal level of reporter activities. In the E-cadherin-positive cells, the constructs containing sequences from À995 to À357 had potent luciferase activities. These results suggest that AML1, HNF3 and p300 may represent positive regulating transcription factors for the E-cadherin gene. The construct E5 had greatly reduced reporter activity. When the 162 bp nucleotides from À357 to À195 were deleted, the reporter activity was restored, suggesting these 162 bp DNA sequences might contain potent repressive element(s) for human E-cadherin gene expression. The construct E6 contains four Sp1-binding and three snail-binding sites and had the highest reporter activity among the constructs tested. These results suggested that Sp1 is a potent positive regulator for human E-cadherin gene expression. These Sp1 sites interacting with Sp1 could even overcome the repressive effect of three Eboxes available for the snail transcription factor. The construct E7 containing two Eboxes that had the least reporter activity indicating snail exerted its most repressive effect on the E-cadherin expression of this construct.
HNF3 as a positive regulator for the human E-cadherin gene expression
The functional assays suggested that HNF3 could be a positive regulator for the human E-cadherin expression. To find out the expression of putative positive regulators for the human E-cadherin gene, RT-PCR was carried out to examine the expression of these transcription factors in various metastatic and nonmetastatic cancer cell lines. As shown in Figure 3 , the expression of E-cadherin had an inverse relation to the expression of snail. In metastatic melanoma cell A2058, breast cancer Figure 1 Structure of E-cadherin regulatory sequence and candidate interacting transcription factors. The 1.2 kb E-cadherin regulatory sequence was cloned from human genomic DNA by PCR. The TF search program was used to find the candidate transcription factors. There are three AML1-binding sites, four HNF3-binding sites, and four snail-binding sites in the human E-cadherin promoter Figure 2 Serial deletion constructs of the E-cadherin regulatory sequence and their activities. Various lengths of E-cadherin promoters were generated by PCR and inserted into reporter vector pGL3. These constructs were transfected into E-cadherin-positive (MCF7) and -negative (MDA231) cells. The luciferase activities were analysed from the cell lysates extracted from cells 48 h after transfection. The activities were the average results of five experiments. The luciferase activities were expressed as folds over that of the control vector cell line MDA231, and MDA435, the expression of Ecadherin was not detectable but the snail was. A similar pattern was also observed in the metastatic lung cancer cell line CLI-5. In most of the colorectal cancer cell lines that we examined, with the exception of LS174T, they all expressed E-cadherin. The RT-PCR results also showed that expression of either HNF3a or b correlated with the expression of E-cadherin. These results suggested that HNF3 might be a positive regulator for human E-cadherin gene expression. Cell lines A2058, MDA231 and MDA435 were used for subsequent experiments in our studies on E-cadherin gene expression.
To characterize further that HNF3 might be a positive regulator for the human E-cadherin gene, vector expressing HNF3 and E-cadherin regulatory constructs were transfected into E-cadherin-positive and E-cadherin-negative cells to examine the effect of HNF3 on the E-cadherin regulatory sequences. As shown in Figure 4 in the E-cadherin-negative cells, the HNF3-expressing vector greatly transactivated the promoter that contained HNF3-binding sites (Figure 4b , E1-E3), whereas the vehicle alone had minimal effect. In E-cadherin-positive cells, the expression of exogenously added HNF3-expressing vector did not showed obvious transactivation effect when compared with the vehicle (Figure 4a ). These results suggested that HNF3 is indeed a positive regulator for human E-cadherin gene expression.
Effect of methylation and chromatin constraint on human E-cadherin gene expression
To explore whether the nonexpression of E-cadherin in metastatic cancer cell lines was due to methylation on the CpG islands (or Sp1-binding sites) on the regulatory sequences of the human E-cadherin gene, A2058, Figure 3 The E-cadherin, HNF3a/b, snail, AML1, and GAPDH transcripts in various tumor cells. Equal amounts (3 mg) of total RNA from various cell lines were converted to cDNAs by reverse transcriptase. These cDNAs were used as template for PCR using primer designed from various genes that covered partial coding sequences Effects of HNF3a transcription factor on the transactivating activity on various E-cadherin regulatory sequences constructs in E-cadherin-positive and -negative cells. (a) Transactivating activity of HNF3a transcription factor on E-cadherin promoter in MCF7. In all, 500 ng of plasmid vectors expressing HNF3a or control plasmids pcDNA3 were cotransfected with 1 mg each of various E-cadherin promoter constructs into E-cadherin-positive cells (MCF7) and analysed for reporter activities as for those in Figure 2 . The activities were normalized by subtracting contribution from control plasmids pcDNA3. (b) Transactivating activity of HNF3a transcription factor on the E-cadherin gene in MDA231. The same constructs as described in (a) but transfected into E-cadherinnegative cells (MDA231) and analysed for reporter activities as described in the experimental procedures MDA231, and MDA435 cells were treated with 2.5-7.5 mM of Aza-dC for 72 h. The RNA and protein were extracted from Aza-dC-treated cells and analysed by RT-PCR and Western blot, respectively, for E-cadherin expression. As shown in Figure 5a , after Aza-dC treatment, E-cadherin RNA and protein could be easily detected in both A2058 and MDA435 cells, whereas in MDA231 cells, E-cadherin RNA and protein remained undetectable after Aza-dC treatment. To further understand the methylation status in A2058, MDA231, and MDA435 cells, we used methylation-specific PCR.
Primers were designed to discriminate between methylated and unmethylated alleles following bisulfite treatment. To provide maximal discrimination in the PCR between methylated and unmethylated DNA, primer sequences were chosen for regions containing cytosines, and CpG islands in E-cadherin gene regulatory sequences from À174 to À58. As shown in Figure 5b , the CpG islands on the E-cadherin regulatory sequences in A2058, MDA231, and MDA435 cells were methylated. Compared with the Aza-dC treatment experiments, we could not detect RNA and protein in MDA231 cells. This suggested that the regulatory sequences of the E-cadherin gene in MDA231 cells appeared to be highly methylated. These results indicated that methylation, at the CpG islands, on the Figure 5 The re-expression of E-cadherin transcripts and proteins after Aza-dc, TSA treatment, or transfected with HNF3 constructs in E-cadherin-negative cells. (a) Methylation of E-cadherin regulatory sequence. (Top) At 72 h after 0, 2.5, and 7.5 mM Aza-dc treatment, RNA was prepared from treated cells. Of total RNA from various cells, 3 mg was converted to cDNAs by reverse transcriptase. These cDNAs was used as template for PCR using primer designed from E-cadherin, HNF3a, snail, and GAPDH that covered partial coding sequences. (Bottom) At 72 h after 7.5 mM Aza-dc treatment, cell extracts were prepared from treated cells. Of cell extract from various cells, 100 mg was analysed by Western blot using anti-E-cadherin and anti-ERK2 antibody. (b) Methylationspecific PCR for E-cadherin. Primer sets used for amplification are designed as methylated (M) and unmethylated (U). Amplification of bisulfite-treated DNA from MCF7, A2058, MDA231, and MDA435 cancer cell lines. (c) Acetylation of E-cadherin regulatory sequences. (Top) At 24 h after 0, 150, and 300 nM TSA treatment, RNA was prepared from treated cells. RT-PCR was carried out as described in (a) (Top). (Bottom) At 24 h after 300 nM TSA treatment, cell extracts were prepared from treated cells. Western blot was carried out as described in (a) (Bottom). (d) HNF3 can induce E-cadherin re-expression in MDA435 and MDA231 cells. (Top) A 2 mg of plasmid vectors expressing HNF3a or control plasmids pcDNA3 was transiently transfected into E-cadherin-negative cells. At 48 h after transfection, RNA was prepared from transfected cells. RT-PCR was carried out as described in (a) (Top). (Bottom) The cells from stable clones were harvested for cell extraction and Western blot was carried out as described in (a) (Bottom). (e) HNF3 relieves the repression of snail binding to E-cadherin promoter. A 2 mg of plasmid vectors expressing HNF3 Fork Head domain (FHD) or wild-type HNF3a was transiently transfected into E-cadherin-negative cells, A2058, MDA231, and MDA435. At 48 h after transfection, RNA was prepared. RT-PCR was carried out as described in (a) (Top) regulatory sequences of the E-cadherin gene was partly responsible for the downregulation of the E-cadherin gene.
To examine whether the constraint on the chromatin structure by HDAC was one of the reasons for nonexpression of E-cadherin in metastatic cancer cells, A2058, MDA231, and MDA435 cells were treated with HDAC inhibitor trichostatin A (TSA) at 150-300 nM for 24 h. The RNA and protein were extracted from the treated cells and analysed for E-cadherin expression. As shown in Figure 5c , E-cadherin RNA could be easily detected in these cell lines treated with TSA, and E-cadherin protein could be detected in TSA-treated MDA231 and MDA435, but not in A2058 cells. Next, when we created transfectants stably expressing either HNF3a or b in A2058, MDA 231, and MDA435 cells, both E-cadherin RNA and protein could be detected in MDA231 and MDA435 cells. However, in the HNF3-transfected A2058 cells only E-cadherin RNA, but not E-cadherin protein, was detected ( Figure 5d ). This result was similar to the TSA-treated A2058 cells in which only E-cadherin RNA, but no E-cadherin protein was detected. It appeared that in A2058 cells there was an additional control on E-cadherin expression at the translational level. These results suggested that constraints by the HDAC on the chromatin played an important role in downregulation of the E-cadherin gene in metastatic cancer cells.
To determine whether relief from the HDAC constraint or demethylation on the chromatin that induced the re-expression of E-cadherin had gone through the activation of HNF3, A2058, MDA231, and MDA435 cells were treated with Aza-dC and TSA or transfected with vector expressing only the Fork Head domain (FHD) of HNF3. The treated cells were examined for the E-cadherin and HNF3 expressions by RT-PCR. As shown in Figure 5a , c, and e, treatment with Aza-dC and TSA induced the re-expression of both HNF3 and Ecadherin, whereas the FHD-transfected cells induced expression of E-cadherin but not of HNF3. These results suggested that the relief from the HDAC constraint by TSA and inhibition of the methylase by Aza-dC activated HNF3, which in turn activated Ecadherin gene expression. The reason why FHD induced E-cadherin will be discussed in the Discussion section.
Functional analysis of AML1-, HNF3-and snail-binding sites
The regulatory sequences of human E-cadherin gene contained multiple-binding sites for AML1, HNF3, and snail transcription factors. It is not clear whether all of these are functional. To determine the roles of these binding sites in the regulation of human E-cadherin gene electrophoresis mobility shift assay (EMSA) and functional analysis were carried out. For the EMSA, purified recombinant AML1a/GST fusion and FHD (the DNAbinding domain of HNF3)/GST fusion proteins were used. The oligonucleotide probes corresponding to the AML1-and HNF3-binding sites on the human Ecadherin regulatory sequences were shown in Figure 6a . Among the AML1-binding sites, the two distal-binding sites (A1 and A2) appeared to have a higher affinity for AML1 protein than the proximal AML1-binding site (A3) (Figure 6b ). This may indicate that A1 and A2 are better positive regulatory elements for the E-cadherin gene. As to the HNF3-binding sites, the distal one, which contained two overlapping HNF3 binding-sites (F1/F2), was found to have a higher affinity for the FHD/GST fusion proteins, whereas the F4 only had moderate affinity for the FHD/GST fusion protein. In contrast, the FHD/GST protein did not bind to the F3 site at all (Figure 6c ). These results suggested that either one or both of the overlapping HNF3-binding sites at the F1/F2 were better positive regulatory elements than that of the F4 site for the E-cadherin gene, and that the F3 site was nonfunctional. Next, we explored whether HNF3 required AML1 or p300 to exert its positive regulatory function for the expression of human Ecadherin gene. As shown in Figure 7a and b, both AML1 and p300 could synergistically facilitate both HNF3a and HNF3b to exert their positive regulatory function on the human E-cadherin gene. The effect was more prominent in MDA231 cells than in MDA435 cells.
When the HNF3-binding sites were mutated, the mutation at the second HNF3-binding site, the F2 site, (i.e. the 3 0 side of the overlapping F1/F2 sites) drastically reduced the transactivation activity of HNF3a, whereas the mutation at the F1 site had only minimal effect. As shown in Figure 6c , the mutation at the F4 site reduced 
can bind to the E-cadherin regulatory sequence. Of the labeled E-cadherin, 1 ng of E-cadherin À931 to À911, E-cadherin À851 to À832, and E-cadherin À386 to À368 oligonucleotides was mixed with recombinant AML1a/GST fusion protein. The reaction products were analyed by EMSA. The competing oligonucleotides homologous probe sequences, consensus binding site of AML1 (5 0 -TGTGGTTGTGGT-3 0 ) and represented mutant of these sites: A1M (5 0 -TGGATCACCTAGAGTCAGGA-3 0 ; A2M (5 0 -GCCGGTAGAGTGGCACACG-3 0 ; and A3M (5 0 -TGATCGCATTGCTG CACT-3 0 ). (c) HNF3 can bind to the E-cadherin regulatory sequence. Of the labeled E-cadherin, 1 ng of E-cadherin À691 to À672, E-cadherin À507 to À483, and E-cadherin À337 to À327 oligonucleotides was mixed with recombinant HNF3 FHD/GST fusion protein. The reaction products were analysed by EMSA. The competing oligonucleotides represented homologous probe sequences, consensus binding site of HNF3 (5 0 -TTATGTTTGTTTA-3 0 ) and mutant of these sites:
the transactivation activity by one-half. These results suggested an order of potency among HNF3-binding sites as positive regulator elements: F2 as the most potent HNF3 elements, followed by F4. F1 and F3 sites did not appear to have a function. The reason why the mutant F3 promoter construct still has more than 50% reduction in HNF3-induced E-cadherin promoter activity will be discussed in the Discussion section. Most studies of the Ebox functions on the human E-cadherin regulatory sequences were focused on the Ebox 1, Ebox 2, and Ebox 3. We used the TF search program and identified an additional Ebox at À464 to À459 in the human E-cadherin gene. To understand the effect of the snail bound to the Eboxes, we generated various mutants of the snail-binding sites in the Ecadherin regulatory sequence construct E2. As shown in Figure 6d , when the single Ebox site was mutated, the Ebox 1 and Ebox 4 had increased luciferase activity, but the mutated Ebox 3 showed no difference when compared with the wild-type E2 construct. When the double mutants of Eboxes were tested, the remaining wild-type Ebox 1 and wild-type Ebox 4 still had repressive functions when exogenous snail expression vector was added, and had the suppressive effect by onehalf and one-third, respectively. In the same doublemutant experiments, the remaining Ebox 3 when added with the snail expression vector seems to be nonfunctional. These results suggested that the Ebox 1 and Ebox 4 allowed the snail to bind and suppressed E-cadherin gene activity and the Ebox 3 may not have a function.
To assess the binding of AML1 and HNF3 to their corresponding element on the regulatory sequences of human E-cadherin at the chromosome setting chromatin immune-precipitation (CHIP) was carried out. We used Flag tagged HNF3a to transfect the E-cadherin-negative cells, MDA231, and used anti-Flag and anti-AML1 antibody (Santa-Cruz) to carry out CHIP assay. As shown in Supplementary Figure 1 , the AML1 and HNF3a bound to their corresponding sites on the chromatin as they did in the in vitro EMSA. The F3 site was shown to be nonfunctional. In the control Flag vector transfectants we used, anti-Flag antibody did not generate the ChIP products. This data demonstrated the absence of the interaction of the HNF3 factor in E-cadherin-negative cells. To observe the interaction Figure 7 Transactivating activity of HNF3, AML1, and p300 transcription factors on E-cadherin gene. (a and b) Synergistic effect between HNF3 and AML1, or HNF3 and p300. In all, 500 ng of plasmid vectors expressing HNF3a, HNF3b, AML1/CBFb, p300, or control plasmids pcDNA3 was cotransfected with 1 mg of E-cadherin À995/135-Luc constructs into E-cadherin-negative cells (MDA435 and MDA231) and analysed for reporter activities as described in Figure 4 . The differences of luciferase-related folds between lanes 2 and 6, or between lanes 2 and 7 have P-value o0.05 based on two-tail student's t-test. (c) HNF3-binding site 2 has most activity for HNF3 binding. A 500 ng of plasmid vectors expressing HNF3a or control plasmids pcDNA3 were cotransfected with 1 mg of wild-type or various HNF3-binding site mutated E-cadherin À995/135-Luc constructs into MDA231 cells and analysed for reporter activities as described in figure 4 . The difference of luciferase related folds between lanes 1 and 2 was not significant (P-value >0.05) based on two-tailed Student's t-test. The differences of luciferase-related folds between lanes 1 and 4, or between lanes 1 and 5, or between lanes 1 and 8 have P-value o0.05 based on two-tailed Student's t-test. (d) The effect of E boxes for snail binding. In all, 500 ng of plasmid vectors pcDNA3 or snail/pcDNA3 was cotransfected with one mg wild-type E-cadherin À517/135-Luc or various snail-binding sites mutated E-cadherin À517/135-Luc constructs into MDA435 cells and analysed for reporter activities as described in Figure 4 . The differences of luciferase-related folds between lanes 1 and 2, or between lanes 1 and 4, or between lanes 1 and 5, or between lanes 1 and 7 have P-value o0.05 based on two-tailed Student's t-test. The difference of luciferase-related folds between lanes 1 and 3 was not significant (P-value >0.05) based on two-tailed Student's t-test between HNF3, p300, and AML1 and the E-cadherin regulatory sequences during tumor progression, we stably expressed HNF3a/pcDNA3 expression vector in E-cadherin-negative cells, MDA231, and MDA435, and used anti-HNF3a/b, anti-p300, and anti-AML1 antibody (Santa-Cruz) to carry out CHIP assay. As shown in Supplementary Figures 2 and 3 , the ChIP product indicated the interaction between HNF3, p300, and AML1 with the endogenous E-cadherin promoter. The ch4 primers did not generate ChIP products. This may be due to the decreasing expression of HNF3a or the lower binding affinity between HNF3a and E-cadherin as they showed in the EMSA. To examine the interaction of endogenous HNF3 and p300 on Ecadherin regulatory sequences, we used E-cadherinpositive cells, MCF7, to carry out CHIP assay. The results in Supplementary Figure 4 showed the HNF3 and p300 could bind to their corresponding sites on the chromatin. In MCF7 cells, AML1 is not expressed (Figure 3) , thus anti-AML1 antibody did not generate ChIP products. These results demonstrated that in vivo HNF3, p300, and AML1 can indeed interact with endogenous E-cadherin promoter during tumor progression.
Expression of HNF3a and HNF3b in metastatic cancer cell lines reduced the motility of cancer cells
The series of experiments described above indicated that HNF3 was a positive regulator for the human E-cadherin gene expression. To examine whether the overexpression of HNF3 in the metastatic cancer cell lines would affect their migratory ability, the metastatic A2058 melanoma cell, MDA231, and MDA435 breast E-cadherin-negative cells expressing either HNF3a/pcDNA3 or HNF3b/pcDNA3 were induced to migrate in serum-free or regular medium. The migration ability is presented as percentage of migrating cells over the total cells in the chamber cancer cells were stably transfected with either HNF3a or HNF3b. And their migratory ability was assessed in transwell assays. As shown in Figure 8a , over-expression of HNF3 in metastatic breast cancer cell lines, MDA231, and MDA435 appeared to change the morphology of these cell lines from spindle shape to more epithelial-looking. The overexpression of HNF3-induced re-expression of the E-cadherin and was located in the cell membrane junctions in MDA231 and MDA435 cells (Figure 8b ). The overexpression of HNF3 also drastically retarded the migratory ability of metastatic cancer cell lines (Figure 8c-e) . These results suggested that HNF3 is a positive regulator for human E-cadherin gene expression and it was able to down-modulate the migrated potential of breast cancer cells, MDA231 and MDA435. However, in melanoma cells, A2058 failed to show morphology changes and membrane staining of E-cadherin. However, the migration assay showed that the over-expression of HNF3 reduced the migratory ability. The HNF3-induced reduction on cell migration in A2058 cells appeared to be independent of E-cadherin function.
Discussion
E-cadherin plays a critical role in establishing cell polarity and cellular differentiation, and in maintaining normal tissue morphology (Birchmeier and Behrens, 1994; Berx et al., 1995) . Downregulation or loss of E-cadherin has been implicated in the gain of invasive potential by carcinomas (Birchmeier and Behrens, 1994; Christofori and Semb, 1999; Hajra and Fearon, 2002) . Genetic changes of the E-cadherin loci have been found only infrequently in tumors, particularly in lobular breast carcinomas and diffuse gastric carcinomas (Becker et al., 1994; Berx et al., 1995; Guilford et al., 1998; Sarrio´et al., 2003) . Most of the evidence accumulated so far has suggested that epigenetic mechanisms involving hypermethylation of CpG islands, chromatin modification, and transcriptional repression were the main mechanisms responsible for E-cadherin silencing in different types of tumors and cancer cell lines (Guilford et al., 1998; Cheng et al., 2001; Sarrio´et al., 2003) .
Decreased expression levels of E-cadherin associated with reduction in adhesion, whereas increased Ecadherin expression decreased motility and invasiveness (Takeichi, 1993; Birchmeier and Behrens, 1994; Berx et al., 1995; Christofori and Semb, 1999) . Promoter hypermethylation of the E-cadherin gene has been implicated in many tumors that downregulated the gene expression (Christofori and Semb, 1999; Cheng et al., 2001) . The results showed that in the E-cadherin regulatory sequences, the extent of CpG islands was either partially methylated or unmethylated. Chromatin structure constraints of the E-cadherin gene in which deacetylation has also been shown to repress the transcription (Hajra and Fearon, 2002; Lachner and Jenuwein, 2002) . Peinado et al. (2004) showed that the snail family transcription factors recruited HDAC and other cofactors to remodel the chromatin structure and to silence the E-cadherin expression. The snail family transcription factors and Twist have been shown to play major roles in E-cadherin repression. These transcription factors act as inducers of the invasion process (Batlle et al., 2000; Yang et al., 2004) . Several studies of E-cadherin promoter revealed regulatory elements including Ebox, CCAAT box, and a GC-rich element located in the 5 0 proximal sequence of the promoter (Bussemakers et al., 1994; Hennig et al., 1995 Hennig et al., , 1996 Faraldo et al., 1997; Giroldi et al., 1997; Ji et al., 1997; Hajra et al., 1999; Rodrigo et al., 1999; Cano et al., 2000; Lelie`vre et al., 2000; Perez-Moreno et al., 2001) . Most of these studies focused mostly on the regulatory sequence near the transcription start site. The regulation of the whole genome context in the human E-cadherin promoter in metastatic and nonmetastatic cancer cells has not yet been established in detail. In metastatic and nonmetastatic cancer cells, the tissue-specific transcription factors may play different roles in up-or downregulating the E-cadherin gene.
In order to investigate why the E-cadherin gene was not expressed in metastatic cancer cells, we prepared genomic DNA from various cancer cell lines and carried out Southern blot to examine whether there are genetic changes, but the results showed no difference among cancer cell lines A2058, MCF7, MDA231, ZR-75-1, CLI-0, CLI-3, and CLI-5 and normal tissue (data not shown). Thus, epigenetic changes affecting E-cadherin gene expression appear to be a major factor of Ecadherin gene regulation. We used Aza-dC treatment and methylation-specific PCR analysis of E-cadherinnegative cells (A2058, MDA231, and MDA 435) and found different metastatic cancer cell lines had different levels for CpG islands methylation on the regulatory sequences in the E-cadherin gene. The results from TSA treatment also indicated that chromatin constraint can affect E-cadherin expression in certain metastatic cancer cells.
Through the analysis of E-cadherin regulatory sequence activities, we defined positive regulatory regions located between À995 and À517 and between À195 and À38 fragments in MDA231 cells, but in MCF7 cells, the positive regulatory regions were located between À995 and À357 and between À195 and À38 fragments. In the region between À517 and À357 in the E4 construct, the presence of p300-and AML1-binding sites would not overcome the presence of snail-binding in MDA231 cells. In the region between À517 to À357 in the E4 construct, there was one binding site each for HNF3, snail, p300, and AML1. Since this HNF3-binding site was nonfunctional, and AML1 and snail were not expressed in MCF7, the E-cadherin expression in MCF7 could be due to HAT activity of p300 and Sp1 binding to unmethylated CpG islands of the E-cadherin regulatory sequence. In MDA231, the repression of the E-cadherin gene could be due to hypermethylation of CpG islands and chromatin constraint. The region between À995 and À517 in E1 to E3 constructs showed that the HNF3, AML1, or p300 transcription factors may play important roles to upregulate E-cadherin promoter activities in both cells. We also identified two negative regulatory elements located between À357 and À195 in the E5 construct and between À38 and 135 in the E7 construct, both in MCF7 and MDA231 cells. In the E7 construct, the snail-binding sites have been shown to play important roles in downregulation of the E-cadherin promoter activity (Cano et al., 2000) , but in the E5 construct, there still were some unknown downregulated elements and investigation on these new elements is still in progress.
Our RT-PCR results showed that in most metastatic cancer cells, E-cadherin and the snail expressed had an inverse relation. We also found that when E-cadherin was expressed, HNF3 was also expressed in most nonmetastatic cancer cells. The cotransfected HNF3a expression vector and E-cadherin-Luc reporter construct in metastatic cancer cells showed that HNF3a could indeed upregulate E-cadherin promoter activity. The gel shift and ChIP assays also showed HNF3 could bind to the regulatory sequence of human E-cadherin gene (see Figure 6c and Supplementary data Figures  1-4) . These results suggested that the transcription factor HNF3 may help the expression of the E-cadherin gene through its binding to the E-cadherin regulatory sequence. These results also showed that AML1 can be expressed both in metastatic (Figure 3, lane 1, 3, 4 , and 12) and nonmetastatic (Figure 3, lane 7and 9) cancer cells. The AML1 may serve as a cofactor that helps the major transcription factors to regulate target gene promoter activities.
The regulatory sequence of human E-cadherin gene had at least four HNF3-, four snail-, three AML1-, and five Sp1-binding elements. The Sp1 transcription factor had been found to upregulate the human E-cadherin gene through binding to the CpG islands region (Hennig et al., 1996) . Many reports have shown that these regions were hypermethylated in carcinoma cells (Christofori and Semb, 1999; Lachner and Jenuwein, 2002) . Multiple-binding sites for HNF3 and snail transcription factor might not indicate that they had equal ability to, respectively, up-and downregulate the E-cadherin gene. Our results showed that the second HNF3-binding element is the most potent in upregulating human E-cadherin gene, whereas the first and third HNF3-binding elements appeared nonfunctional. The third HNF3-binding site mutant showed more than 50% activity when the exogenous HNF3 was added. The third HNF3-binding site is near the Ebox4. Two of these transcription factors may compete with each other to bind their respective sites adjacent to each other. The pervious report showed that the downregulation of E-cadherin by snail required the cooperation with Sin3A and HDAC to form a large complex (Peinado et al., 2004) . The mutation at the third HNF3-binding site may influence the binding ability of a member of the snail complex or some other downregulated transcription factor members. Mutation experiments on snail-binding elements showed that the Ebox 3 is nonfunctional, whereas Ebox 1 had the most repression ability compared with Ebox 4 on human E-cadherin gene expression. Ebox 2 has been functionally characterized in human E-cadherin gene promoter (Batlle et al., 2000; Hajra and Fearon, 2002) . They used Ebox 1, 2, and 3 as models and indicated the most repressed effect was of Ebox 1 and not Ebox 2 and Ebox 3. In our results, we demonstrated Ebox 3 was nonfunctional. Even though we did not create a mutant site of Ebox 2, this would not affect the results.
Our functional assay also showed that HNF3 cooperated with AML1 and p300 in upregulating the E-cadherin gene. The HNF3 stable transfectants of metastatic MDA231 and MDA435 cells showed the reexpression of the E-cadherin gene. Interestingly, when only FHD of HNF3 was expressed in E-cadherinnegative cells, E-cadherin gene re-expression was also detected. This could be due to the fact that the FHD had been showed to interact with p300/CBP to activate HAT activity and to upregulate the target gene expression (Soutoglou et al., 2000 (Soutoglou et al., , 2001 . These results suggested HNF3 may cooperate with p300/CBP and upregulate E-cadherin gene expression. Upon Aza-dC and TSA treatments, transfection with wild-type HNF3, or transfection with FHD of HNF3 into the E-cadherinnegative cells did not affect snail expression. The results suggested that overexpression of HNF3 or inhibition of the methylase by Aza-dC or inhibition of HDAC activities by TSA will result in the relief of repressive effect by snail on E-cadherin expression. These results indicated that in context of larger regulatory sequences, the presence of HNF3 may play a dominant role to upregulate human E-cadherin gene expression. It is likely that this positive regulation by HNF3 on E-cadherin gene expression is through cooperation with p300/CBP to remodel the chromatin structure (Soutoglou et al., 2000 (Soutoglou et al., , 2001 . It can even overcome the presence of snail.
The HNF3 transcription factors had been shown to be involved in cell differentiation (Shigeaki et al., 2002) . Our results indicated that HNF3 could induce the E-cadherin expressed in metastatic breast cancer cells, MDA231 and MDA435, and change morphology from mesenchymal looking to epithelial looking. Also, its expression in metastatic breast cancer cells would reduce cell motility. In melanoma cells A2058, the migration assay showed the reduction of cell motility, but we did not detect the expression of E-cadherin either by Western blot or by immunofluorescence (IF) assay after overexpressing HNF3. We speculate that HNF3 may induce genes other than E-cadherin that may be involved in reducing cell migration.
The HNF1, HNF3, and HNF4 are transcription factors detected in the liver and play critical roles in liver morphogenesis (Cereghini, 1996) . The HNF1 and HNF3 shared homology with Drosophila homeotic gene Fork Head, but the HNF4 belonged to the steroid hormone receptor superfamily (Pani et al., 1992) . A previous work established that HNF4a-regulated epithelial morphogenesis and induced mesenchymal to epithelial transition from fibroblast cells into epithelial cells. Expression of HNF4a resulted in activation of E-cadherin (Parviz et al., 2003) . The lack of HNF3 resulted in a reduction of HNF1 and HNF4 gene expression, and suggested that HNF3 regulated a transcription factor network required for cell differentiation (Duncan et al., 1998) . This gene may also play a role as a tumor suppressor in lung cancer (Halmos et al., 2004) . HNF3 bound to DNA as a monomer through a winged-helix motif (Cirillo et al., 1998) . The FHD of HNF3 was able to bind to the DNA motif and can also interact with other cofactors (Braun and Suske, 1998) . The previously published results showed that this domain could interact with CBP/p300 and activate the HAT activity (Soutoglou et al., 2000 (Soutoglou et al., , 2001 .Therefore, the HNF3 may play a positive role in E-cadherin gene expression and may repress metastatic potential of cancer cells.
Our study on the regulation of E-cadherin gene expression in the metastatic and nonmetastatic cancer cells showed that methylation states, chromatin constraint and snail family transcription factors play important roles in the downregulation of E-cadherin gene expression, thus enhancing metastatic potential. In contrast, transcription factor HNF3a, AML1, and p300 can cooperate to enhance E-cadherin gene expression and thus repress the metastatic potential of cancer cells. These results demonstrated that the transcription factor HNF3 can induce E-cadherin re-expression in highly metastatic breast cancer cells and change the cell morphology and motility. Each metastatic cancer cell line uses different and more than one mechanism to upor downregulate E-cadherin gene expression, thus affecting its metastatic ability.
Materials and methods
RNA isolation and RT-PCR
When cells reached 80% confluence, they were harvested and the RNA was extracted using the acid quanidinium method. The RNA (3 mg) from each cell line was converted into single strand cDNA (sscDNA) primed by oligo-dT using the SuperScript preamplification system for first-strand cDNA synthesis kit (GibcoBRL Life Technologies, Inc.) following the vender's protocol. Of each sscDNA, 1 ml was used as a template to generate E-cadherin, HNF3a, HNF3b, snail, AML1, and GAPDH partial sequence of cDNA. The primer sequences of various genes are given in Supplementary Data. The PCR program was 951C, 5 min followed by 35 cycles of 951C, 1 min, 601C, 1 min, and 721C, 1 min. At the end of the PCR, the reaction was extended for 8 min at 721C, then cooled down to 41C. Aliquots of PCR products were analysed by electrophoresis in 1% agarose. The expected cDNA products of the E-cadherin, HNF3a, HNF3b, snail, AML1, and GAPDH were 550, 500, 500, 450, 350, and 350 bps.
Generation of plasmids, expression vectors, and stable transfectants
The E-cadherin regulatory sequences from 995 bp upstream to 135 bp downstream of the E-cadherin transcription start site was cloned by genomic PCR using human genomic DNA as a template. Various size deletions of the promoter were generated, also by PCR, with various 5 0 primers and a fixed 3 0 primer. The sequences of these primers are shown in Supplementary Data. To facilitate the functional analysis of various E-cadherin regulatory sequence constructs, the 5 0 end primers were attached with the KpnI site and the 3 0 end primer was attached with the SacI site. The PCR program was 951C, 5 min followed by 35 cycles of 951C, 1 min, 561C, 1 min, and 721C, 1 min. At the end of the PCR, the reaction was extended for 8 min at 721C then cooled down to 41C. Aliquots of PCR products were analysed by electrophoresis in 1% agarose. The expected sizes of PCR fragments were 1130, 968, 812, 652, 492, 330 , and 173 bps. All the serial deleted E-cadherin promoter fragments were cloned into luciferase reporter vector pGL3 (Promega).
The AML-1a cDNA was obtained from Dr H Miyoshi, National Cancer Research Institute, Tokyo, Japan. The p300/ CBP was obtained from Dr Han Zon Lee, National Dong Hwa University, Hualien, Taiwan. The CBFb and snail cDNA was generated by RT-PCR using sscDNA derived from A2058. The cDNA encoding only the FHD of HNF3 was also generated by PCR. All cDNAs were inserted into the eukaryotic expression vector pcDNA3 for cotransfection experiments, as described in the text. The AML-1a and FHD of HNF3 cDNAs were also inserted into the prokaryotic expression vector pGEX-KG (Guan and Dixon, 1991) . The recombinant constructs were transformed into Escherichia coli strain BL21 (PROMEGA). The purification of GST fusion protein was performed as described (Liu et al., 2004) .
All the E-cadherin regulatory sequence mutant constructs were generated by site-directed mutagenesis PCR kit (Strategene) with the following primers. The primers of the HNF3 and snail-binding sites mutant constructs are given in Supplementary Data. The programs of the PCR was 951C, 5 min followed by 25 cycles of 951C, 1 min, 561C, 2 min, and 721C, 10 min, then cooled down to 41C. The PCR products were incubated with 1 ml DpnI (BioLab). The DpnI-treated mutated reporter constructs were transformed into E. coli strain XL1-blue (Strategene). All mutant constructs were verified by restriction enzyme digestion because new restriction sites were created into these mutated sites.
The A2058-HNF3a, A2058-HNF3b, A2058-pcDNA3, MDA231-HNF3a, MDA231-HNF3b, MDA231-pcDNA3, MDA435-HNF3a, MDA435-HNF3b, and MDA435-pcDNA3 transfectants were generated by stable transfection with 10 mg of plasmids pcDNA3-HNF3a, pcDNA3-HNF3b, and empty vector pcDNA3, respectively, and selection with 400 mg of G418/ml for one month.
Cell culture and cell treatment
The following cell lines were used in this study: melanoma cell line: A2058; breast cancer cell lines: MCF7, MDA231, MDA435, and ZR-75-1; colon cancer cell line: LOVO, HCT116, colo205, and Ls174T; lung carcinoma cell lines: CLI-0, CLI-3, and CLI-5. Colon cancer cell line HCT116 was grown in Mccoy media (Sigma) supplemented with 10% FCS) (Biowest). Breast cancer cell line ZR-75-1, colon cancer cell line colo205, and Ls174T and lung carcinoma cell lines were grown in RPMI media (Sigma) supplemented with 10% FCS. The other cell lines were grown in DMEM media (Sigma) supplemented with 10% FCS. Cells were grown at 371C in 5% CO 2 atmosphere. The 5-Aza-2 0 -deoxycytidine (Aza-dc) (Calbiochem), a potent inhibitor of DNA methylase, was dissolved in ddH 2 O and added to the culture medium at 2.5 and 7.5 mM for 72 h. A corresponding volume of ddH 2 O was added to the control untreated cells. Tricostatin A (TSA) (Sigma), an HDAC inhibitor, was dissolved in ethanol and added to the culture medium at 150 and 300 nM for 24 h. A corresponding volume of ethanol was added to the control untreated cells.
Transient transfection and luciferase assay
Cells were plated 12-24 h before transfection at 1-2 Â 10 5 cells per well in a six-well cell culture plate. In all, 2 mg of various DNA constructs and 0.3 ng of Renilla construct (Promega) were mixed with 10 ml of Superfect (Qiagen). The mixture was incubated at room temperature for 10 min. After washing, the cells with 1 Â PBS, the DNA/Superfect mixtures were transferred to the cells and incubated at 371C in a CO 2 incubator for 24 h. When cotransfection with constructs expressed various transcription factors, appropriate control plasmids such as pcDNA3 and pGL3 were also transfected into separate cultured cells as controls, and DNA was maintained in equal amounts. Subsequently, the transfected cells were washed with 1 Â PBS and cultured for an additional 48 h in DMEM with 10% FCS. At the end of 48 h incubation, the transfected cells were lysed with reporter lysis buffer (Promega). The enzymatic activity was measured for firefly and Renilla luciferase using Dual-luciferase Reporter assay System (Promega) with a luminometer. All luciferase assays were carried out in duplicate or triplicate and experiments were carried out at least twice.
Cell extraction and Western blot
After washing cells with 1 Â PBS twice, cells were scraped with 0.5 ml 1 Â PBS and collected in a microcentrifuge tube. The cells were spun down at 3000 r.p.m for 5 min, and the supernatants were discarded. Each tube of pellets was resuspended with 1 ml RIPA buffer (50 mM Tris, 0.5% NP40, 150 mM NaCl, 20% glycerol, and 2 mM DTT) containing protease inhibitor (Roche), and the samples were incubated on ice for 30 min. Then these samples were spun at 10 000 r.p.m for 10 min at 41C, and the supernatants were collected. The protein concentration of cell extracts was measured using BioRad protein assay (Bio-Rad). Of total cell extracts, 1 mg from each cell line was electrophoresed in SDS/polyarcrylamide gel (0.1 and 6%, respectively). Then the separated proteins were transferred to PVDF Transfer Membrane (Perkin-Elmer) for Western blot analysis. Membranes were blocked in 5% nonfat dry milk in 1 Â PBST (1 Â PBS containing 0.1% Tween 20) for 1 h. The membrane was then incubated in primary antibody diluted in 1 Â PBST (1 : 2000 dilution) for 1 h, then washed with 1 Â PBST for 15 min three times. Membranes were then incubated in HRP-conjugated secondary antibody at room temperature for one hour and subsequently washed with 1 Â PBST three times. The membrane was incubated in Western lightning chemiluminescence Reagent (Perkin-Elmer) and blotted excess chemiluminescence substrate for 1 min then exposed to Kodak BioMax Light Film for 1-5 min.
Methylation-specific PCR
Genomic DNA (2 mg) in a volume of 50 ml was denatured with 1 ml 10 M NaOH and incubated at 371C for 10 min. Then 520 ml of freshly prepared 3 M sodium bisulfite (pH5.0) and 30 ml of 10 mM hydroquinone were added to the denatured DNA. The samples were evenly distributed into six 0.2 ml PCR tubes and 20 cycles of 991C, 30 min then 501C, 15 min were performed. The bisulfite-treated DNA samples were purified with Wizard DNA Clean-Up system kit (PROMEGA). The treated and purified DNA samples were resuspended in 50 ml ddH 2 O and 1.5 ml 10 M NaOH. After 10 min at room temperature, 250 ml 3 M NH 4 OAc and 800 ml 100% alcohol were added, mixed, and then centrifuged at 13 000 r.p.m. for 20 min at 41C. After removing the supernatants, the DNA pellets were washed with 1 ml of 70% alcohol and air dried. The DNA pellets were then dissolved in 50 ml ddH 2 O. Of each modified DNA sample, 50 ng of each modified DNA sample was used for PCR. Primer designs specific for methylated DNA were forward: 5 0 -TTAGGTTAGAGGGTTATCGCGT-3 0 and reversed: 5 0 -TAACTAAAAATTCACCTACCGAC-3 0 and primers for unmethylated DNA were: forward: 5 0 -TAATTT TAGGTTAGAGGGTTATTGT and reversed: 5 0 -CACAAC CAATCAACAACACA. This primer information were derived from E-cadherin regulatory sequences as described (Herman et al., 1996) . The methylation-specific PCR fragment is 115 bp and the unmethylation-specific fragment is 97 bp. PCR products were analysed by electrophoresis on a 2% agarose gel and visualized after ethidium bromide staining.
Electrophoresis mobility shift assay
To prepare oligonucleotides for the EMSA, 500 ng each of sense and antisense oligonucleotides were mixed in 100 ml water, heated at 601C for 15 min, and then slowly cooled down to 41C. Double-stranded oligonucleotides (100 ng) were end labeled with 32 P (specific activity, 1-5 Â 10 7 /mg). For the EMSA reaction, 1 ng of labeled probe (10 000-50 000 cpm/sample) was mixed with equal amounts of bacterially synthesized recombinant proteins (3 mg/ml) in 40 ml buffer containing 10 mM HEPES pH 7.9, 10 mM KCl, 5 mM MgCl 2 , 1 mM DTT, 1 mg poly(dI-dC), and 10% glycerol. The mixtures were kept on ice for 1 h, then loaded onto a 6% polyarcrylamide gel and electrophoresed at 150 V in 1 Â TBE buffer (22.5 mM Trisborate, 0.5 mM EDTA pH 8.0).
Migration assay
Cell migration was performed using 8.0-mm pore size Transwell inserts (NUNC). The six-well dish was prepared by added 1.5 ml medium to each well. An insert was placed into each prepared well with the membrane toward the well bottom. Cell suspension (2 Â 10 5 cells and 1.5 ml medium) was added to the interior of each insert. After a 72-h incubation, each well was trypsinized and the transwell cells were stained with Trypan blue. Transwelled cells divided by the total cell number was calculated. Each data point represented the average of three or four individual experiments, carried out in duplicate, and error bars represented the standard error of the mean.
IF analysis
For IF, stable transfected cells were grown on coverslips and were fixed in 1% formaldehyde (200 ml of formaldehyde mix with 7.2 ml PHEM) (PHEM containing 60 mM PIPES, 25 mM, pH6.9 HEPES, 10 mM EGTA, and 4 mM MgCl 2 ) for 10 min and was used 1% CHAPS for perforating in RT for 4 min. Samples were then blocked three times with skim milk in RT for 10 min and stained for mouse anti-E-cadherin antibody (Snata crus) (1 : 100) in 371C for 1 h. The samples were washed with MBST (10 mM, pH7.4 MOPS, 150 mM NaCl, 0.05% Tween-20) three times in RT for 10 min and then stained for secondary antibody, anti-mouse (Molecular Probes) (1 : 300) in 371C for 1 h. The cells were mounted on p-phenylenediamine and the preparations were visualized with IF microscope.
